Medical Product Guide» Osteoporosis http://blog.medicalproductguide.com A comprehensive guide to medical products for medical professionals Mon, 20 Jun 2011 12:36:09 +0000 en hourly 1 http://wordpress.org/?v=3.1.3 Mylan Receives FDA Approval For Nabumetone http://blog.medicalproductguide.com/2010/07/16/mylan-receives-fda-approval-nabumetone/ http://blog.medicalproductguide.com/2010/07/16/mylan-receives-fda-approval-nabumetone/#comments Fri, 16 Jul 2010 09:09:23 +0000 Jim Marino http://www.medicalproductguide.com/blog/?p=459 Mylan Inc. received the FDA approved for its generic version of the osteoarthritis and rheumatoid arthritis drug Nabumetone. The FDA approval allows Mylan to sell 500 milligram and 750 milligram tablets of Nabumetone. It is a nonsteroidal anti-inflammatory drug, which is a popular type of arthritis and inflammation treatment.

Read the full story here.

]]> http://blog.medicalproductguide.com/2010/07/16/mylan-receives-fda-approval-nabumetone/feed/ 0 Journal shows possible tie between depression and bone metabolism http://blog.medicalproductguide.com/2009/01/19/journal-shows-possible-tie-between-depression-and-bone-metabolism/ http://blog.medicalproductguide.com/2009/01/19/journal-shows-possible-tie-between-depression-and-bone-metabolism/#comments Mon, 19 Jan 2009 23:27:26 +0000 Melissa Chang http://www.medicalproductguide.com/blog/2009/01/19/journal-shows-possible-tie-between-depression-and-bone-metabolism/ Image of journalA study in the current issue of the European Journal Psychotherapy and Psychosomatics reveals that the association between psychiatric illness, in particular depression, and osteoporosis has been the subject of a growing body of research yielding various findings, although most identify some effect on bone.

In addition to medication-related processes and/or modifiable lifestyle factors associated with mood disturbances, endocrine and immune alteration secondary to depression may play a pathogenetic role in bone metabolism.

Additional longitudinal studies, with the advantage of temporal sequencing, remain to be conducted, as well as research into potential mechanisms surrounding the association. Nevertheless, the current findings are of clinical relevance, given the health burden of both depression and osteoporosis.

 Check out the full article in ScienceDaily.com.

]]> http://blog.medicalproductguide.com/2009/01/19/journal-shows-possible-tie-between-depression-and-bone-metabolism/feed/ 0 Teva gets FDA nod for generic Fosamax http://blog.medicalproductguide.com/2008/02/07/teva-gets-fda-nod-for-generic-fosamax/ http://blog.medicalproductguide.com/2008/02/07/teva-gets-fda-nod-for-generic-fosamax/#comments Thu, 07 Feb 2008 21:56:17 +0000 Jim Marino http://www.medicalproductguide.com/blog/2008/02/07/teva-gets-fda-nod-for-generic-fosamax/ Teva LogoMerck & Co.’s Fosamax (alendronate sodium) now has competition. Teva Pharmaceutical Industries Ltd. has received FDA approval for a generic version of Fosamax for osteoporosis treatment. The generic has been approved in doses of 5 mg, 10 mg, 35 mg, 40 mg and 70 mg. The company has marketing exclusivity for 180 days and plans to commence shipment of the drug immediately.

]]> http://blog.medicalproductguide.com/2008/02/07/teva-gets-fda-nod-for-generic-fosamax/feed/ 0